Key facts

43linked publications

0meta-analyses & reviews

21randomised trials

0conditions studied

Analyses mentioning L. crispatus

Study	Type	Year
VIBRANT: A phase 1 randomized trial of multi-strain vaginal L. crispatus live biotherapeutic products in people with bacterial vaginosis. Cell host & microbe	RCT	2026
Clinical and vaginal microbiota effects of oral Lactobacillus crispatus M247 combined with vaginal laser therapy in menopausal women with atrophic vulvovaginitis: a prospective, randomized and controlled study. Lasers in medical science	RCT	2026
Vaginal microbiota impacts of a Lactobacillus crispatus live biotherapeutic and predictors of colonization in randomized controlled trial. Cell host & microbe	RCT	2026
Postbiotics originated from Lactobacillus crispatus NCU-31 improves vulvar lichen sclerosus: a randomized, double-blind controlled trial. BMC microbiology	RCT	2026
Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial. The Lancet. Microbe	RCT	2025
Supplementation with heat-sterilized Lactobacillus crispatus strain KT-11 stimulates the T cell-related immune function of healthy Japanese adults: A pilot randomized, placebo-controlled, double-blind, parallel-group study. Nutrition research (New York, N.Y.)	RCT	2025

Showing 6 of 43 linked publications, highest evidence first.